2-Azetidinone cholesterol absorption inhibitors: Structure-activity relationships on the heterocyclic nucleus

Journal of Medicinal Chemistry

Volumn 39, Issue 19, 1996, Pages 3684-3693

  Clader, John W ^a   Burnett, Duane A ^a   Caplen, Mary Ann ^a   Domalski, Martin S ^a   Dugar, Sundeep ^a   Vaccaro, Wayne ^a   Sher, Rosy ^a   Browne, Margaret E ^a   Zhao, Hongrong ^a   Burrier, Robert E ^a   Salisbury, Brian ^a   Davis Jr , Harry R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 PIPERIDEINE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING); NEUROTOXIN;

ARTICLE; CATALYSIS; DIAGNOSTIC ACCURACY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; NEUROTRANSMISSION; OXIDATION; PREDICTION;

ABSORPTION; ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL ESTERS; CRICETINAE; HYDROGEN BONDING; LIVER; MALE; MESOCRICETUS; MICROSOMES, LIVER; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; RATS; STEROL O-ACYLTRANSFERASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9544237127     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960405n     Document Type: Article

References (24)

1. McGill, H. C., Jr. Geographical Pathology of Atherosclerosis; Williams and Wilken Co.: Baltimore, 1985.
2. (a) The Nutrition Committee of the American Heart Association. Dietary guidelines for healthy American Adults: a statement for physicians and health professionals. Circulation 1988, 77, 721A-724A.
3. (b) The Expert Panel. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J. Am. Med. Assoc. 1993, 269, 3015-3023.
4. For a recent review of pharmacological approaches to the treatment of atherosclerosis, see: Krause, B. R.; Sliskovic, D. R.; Bocan, T. M. A. Emerging therapies in atherosclerosis. Exp. Opin. Invest. Drugs 1995, 4, 353-387.
5. Although bile acid sequestrants have been shown to inhibit cholesterol absorption in animals (see ref 13), their effect on serum cholesterol in humans is due mostly to inhibition of bile acid reabsorption and a resultant increase in hepatic 7α-hydroxylase activity.
6. Roth, B. D.; Blankley, C. J.; Hoefle, M. L.; Holmes, A.; Roark, W. H.; Trevedi, B. K.; Essenburg, A. D.; Kieft, K. A.; Krause, B. R.; Stanfield, R. L. Inhibitors of Acyl-CoA:Cholesterol Acyltransferase. 1. Identification and Structure-Activity Relationships of a Novel Series of Fatty Acid Anilide Hypocholesterolemic Agents. J. Med. Chem. 1992, 35, 1609-1617.
7. Largis, E. E.; Wang, C. H.; deVries, V. G.; Schaffer, S. A. CL277,-082: A novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. J. Lipid Res. 1989, 30, 681-690.
8. Clader, J. W.; Berger, J. G.; Burrier, R. E.; Davis, H. R.; Domalski, M.; Dugar, S.; Kogan, T. P.; Salisbury, B.; Vaccaro, W. Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effects of Polar Groups on in Vitro and in Vivo Activity. J. Med. Chem. 1995, 38, 1600-1607.
9. Lopenzcandales, A.; Bosner, M. S.; Spilburg, C. A.; Lange, L. G. Cholesterol transport function of pancreatic cholesterol esterase: directed sterol uptake and esterification in enterocytes. Biochemistry 1993, 32, 12085-12089.
10. 14C]-cholesterol absorption in animal models. FASEB J. 1992, 6, A1388.
11. (a) Davignon, J. Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 21 (2), 139-146 and references cited therein.
12. (b) McCarthy, P. A.; DeNinno, M. P.; Morehouse, L. A.; Chandler, C. E.; Bangerter, F. W.; Wilson, T. C.; Urban, F. J.; Walinsky, S. W.; Cosgrove, P. G.; Duplantier, K.; Etienne, J. B.; Fowler, M. A.; Lambert, J. F.; O'Donnel, J. P.; Pezzullo, S. L.; Watson, H. A., Jr.; Wilkins, R. W.; Zaccaro, L. M.; Zawistoski, M. P. 11-Ketotigogenin Cellobioside (Pamaqueside): A Potent Cholesterol Absorption Inhibitor in the Hamster. J. Med. Chem. 1996, 39 (10), 1935-1937.
13. Burnett, D. A.; Caplen, M. A.; Davis, H. R., Jr.; Burrrier, R E.; Clader, J. W. 2-Azetidinones as Inhibitors of Cholesterol Absorption. J. Med. Chem. 1994, 37 (12), 1733-1736.
14. Bergman, M.; Morales, H.; Mellars, L.; Kosoglou, T.; Burrier, R.; Davis, H. R.; Sybertz, E. J.; Pollare, T. 12th International Symposium on Drugs Affecting Lipid Metabolism, Houston, TX, Nov. 7-10, 1995.
15. Salisbury, B. G.; Davis, H. R.; Burrier, R. E.; Burnett, D. A.; Boykow, G.; Caplen, M. A.; Clemmons, A. L.; Compton, D. S; Hoos, L. M.; McGregor, D. G.; Schnitzer-Polokoff, R.; Smith, A. A.; Weig, B. C.; Zilli, D. L.; Clader, J. W.; Sybertz, E. J. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Atherosclerosis 1995, 115, 45-63.
16. For a discussion of the activity of other lactams, see: Dugar, S.; Kirkup, M. P.; Clader, J. W.; Lin, S.-I.; Rizvi, R.; Snow, M. E.; Davis, H. R.; McCombie, S. W. Gamma-Lactams and related compounds as Cholesterol Absorption Inhibitors: Homologs of the beta-Lactam Cholesterol Absorption Inhibitor SCH 48461. Bioorg. Med. Chem. Lett. 1995, 5, 2947-2952.
17. Hart, D. J; Ha, D.-C. The Ester Enolate-Imine Condensation Route to β-Lactams. Chem. Rev. 1989, 89, 1447-1465.
18. Browne, M.; Burnett, D. A.; Caplen, M. A.; Chen, L.-Y.; Clader, J. W.; Domalski, M.; Dugar, S.; Pushpavanem, P.; Sher, R.; Vaccaro, W.; Viziano, M.; Zhao, H. trans Diastereoselective synthesis of 3-alkyl substituted beta lactams via the acid chloride-imine reaction of non-activated acid chlorides. Tetrahedron Lett. 1995, 36 (15), 2555-2558
19. Arrieta, A.; Cossio, F. P.; Palomo, P. Synthesis of β-lactams from acetic acids and imines induced by phenyl dichlorophosphate reagent. Tetrahedron 1985, 1703-1712.
20. For details on both models as well as leading references, see refs 7, 11, and 13.
21. The absolute stereochemistry of SCH 48461 has been shown unambiguously to be 3R,4S, see: Burnett, D. A. Asymmetric Synthesis and Absolute Stereochemistry of Cholesterol Absorption Inhibitor, SCH 48461. Tetrahedron Lett. 1994, 35 (40), 7339-7342 and references cited therein.
22. An investigation of the metabolism of SCH 48461 shows no evidence for ACAT inhibitory metabolites and no evidence for loss of stereochemistry at either of the chiral centers. Details of these studies will be presented elsewhere.
23. Dugar, S.; Clader, J. W.; Chan, T.-M.; Davis, H., Jr. Substituted 2-Azaspiro[5.3]nonan1-ones as Potent Cholesterol Absorption Inhibitors: Defining a Binding Conformation for SCH 48461. J. Med Chem. 1995, 38, 4875-4877.
24. Chuang, C.; Lapin, S. C.; Schrock, A. K.; Schuster, G. B. J. Am. Chem Soc. 1985, 14, 4238.